Welcome to our dedicated page for Coeptis Therapeutics news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics stock.
Coeptis Therapeutics Holdings Inc. reports corporate-status, capital-structure and biotechnology developments associated with the company that became Z Squared Inc. after a completed merger and name change. News tied to COEP includes shareholder voting matters, governance updates, operating and financial results, and material agreements.
The company’s biotechnology-related updates include clinical or regulatory disclosures and licensing activity involving majority-owned SNAP Biosciences, the SNAP-CAR NK cell therapy platform, and oncology applications using small-molecule adaptor technology. Later corporate updates center on capital structure, security-status changes and formal transaction disclosures.
Coeptis Therapeutics has entered into a strategic agreement with Statera Biopharma to acquire its toll-like receptor 5 (TLR5) agonist platform, including the clinical-stage candidate entolimod, for $6 million. The agreement is subject to further negotiation and financing conditions. Entolimod is being developed to treat acute radiation syndrome and has shown potential in treating neutropenia and anemia in cancer patients. This acquisition is expected to enhance Coeptis' pipeline and address underserved medical needs in light of the current geopolitical climate.
Coeptis Therapeutics (OTC PINK: COEP) has established a Scientific Advisory Board (SAB) to guide the development of its cancer cell therapy platforms, particularly the CD38-GEAR-NK and CD38-Diagnostic technologies. The SAB includes leading researchers from the Karolinska Institutet: Dr. Evren Alici, Dr. Hans-Gustaf Ljunggren, and Dr. Arnika Kathleen Wagner. Their expertise is expected to enhance the company's product portfolio targeting CD38-associated cancers, with an initial focus on multiple myeloma.
Coeptis Therapeutics (OTC PINK: COEP) announced on Aug. 19, 2021, its acquisition of two technology assets targeting CD38 cancers from VyGen-Bio, Inc. The assets are CD38-GEAR-NK, a cell therapy product, and CD38-Diagnostic, an in vitro diagnostic tool. This acquisition follows previous option agreements made on May 18, 2021, and aims to enhance treatment paradigms for multiple myeloma and other cancers. Coeptis plans to initiate development programs, highlighting the partnership's potential as a significant value driver for the company.